Anti-Hu Ab

Laboratory assay overview

Evaluation of patients with suspected paraneoplastic neurologic syndrome such as encephalomyelitis.

Laboratory assay overview

This test should be considered for the differential evaluation of patients who present with a subacute neurological disorder of undetermined etiology, especially when nerve conduction velocity studies reveal lower amplitudes with relatively preserved conduction velocity.

Laboratory assay overview

This test should be considered for the differential evaluation of patients who present with rapidly progressive dementia of undetermined etiology, especially with cognitive impairment and neuronal degeneration.

Laboratory assay overview

This test can be utilized for evaluating symptoms indicative of idiopathic dysautonomia or discerning between autoimmune dysautonomia and the consequences of chemotherapy in individuals undergoing cancer treatment and exhibiting autonomic symptoms. Autoimmune dysautonomia encompasses disorders affecting the autonomic nervous system's components, triggered by neural-specific IgG or effector T cells. It presents as idiopathic or paraneoplastic, with variable onset and severity. Pandysautonomia manifests gradually with symptoms like impaired pupillary light reflex, anhidrosis, orthostatic hypotension, cardiac arrhythmias, gastrointestinal dysmotility, sicca manifestations and bladder dysfunction. Limited dysautonomia confines symptoms to specific areas, often milder, including sicca manifestations, postural orthostatism, cardiac arrhythmias, bladder dysfunction or gastrointestinal dysmotilities. Diagnosis relies on identifying objective abnormalities via autonomic reflex testing, thermoregulatory sweat test or gastrointestinal motility studies. The most common autoantibody, the neuronal ganglionic alpha-3-acetylcholine receptor (AChR) autoantibody, directly affects dysautonomia severity. Patients with this autoantibody often have cancer, including small-cell lung carcinomas, thymoma, lymphoma and adenocarcinomas. Cancer risks stem from personal or family history, smoking or carcinogen exposure. Early cancer detection improves neurological outcomes. Autoantibodies to other proteins, like antineuronal nuclear antibody-type 1 (ANNA-1) and collapsin response-mediator protein-5 neuronal (CRMP-5-IgG), also mark dysautonomia, predicting specific neoplasms.

Laboratory assay overview

For the detection of antineuronal autoantibodies that help in the diagnosis of paraneoplastic syndromes and autoimmune encephalopathies and related conditions

Laboratory assay overview

For the detection of antineuronal autoantibodies that help in the diagnosis of paraneoplastic syndromes and autoimmune encephalopathies and related conditions

Laboratory assay overview

This test can assist in the diagnosis (paraneoplastic or idiopathic autoimmune) and aid distinction from other causes of myelopathy (sarcoidosis, vascular disease, multiple sclerosis). Early testing may assist in early diagnosis of occult cancer, prompt initiation of immune therapies, or both.

Laboratory assay overview

For the detection of antineuronal autoantibodies that help in the diagnosis of paraneoplastic syndromes and autoimmune encephalopathies and related conditions

Laboratory assay overview

This test is used for the detection of antineuronal autoantibodies that help in the diagnosis of paraneoplastic syndromes.